The risks of hip, Colles' and spine fractures were also reduced. Unfortunately, tamoxifen was associated with increased risks of endometrial cancer, stroke, pulmonary embolus, deep vein thrombosis and cataract. The National Cancer Institute sponsored a workshop in July,1998 to review the information on risks in the presence and absence of tamoxifen and to develop methods to weigh the risks and benefits of tamoxifen and to convey this information to women who were seeking advice as to its use. The risks and benefits of tamoxifen vary by age and race and by the initial risk of breast cancer.
Tamoxifen is most beneficial for younger women with an elevated risk of breast cancer.
We shall review the information on risks and benefits, methods used to summarize this information and to identify classes of women likely to have a net benefit, and uncertainties and research needs.